BibTex RIS Kaynak Göster

The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome

Yıl 2012, , 307 - 312, 01.09.2012
https://doi.org/10.5799/ahinjs.01.2012.03.0169

Öz

Objectives: The aim of this study is to investigate relationships between biochemical parameters and interleukin-6 according to the ovarian morphology in polycystic ovary syndrome (PCOS). Materials and methods: A total of 85 patients with PCOS were divided into three groups according to the ultrasonographic examination of the ovaries; group 1 (with no polycystic image at any of the ovaries, n=22), group 2 (with polycystic image at only one ovary, n=41), and group 3 (with polycystic image at both of the ovaries, n=22). Serum interleukin 6 (IL-6), hormone levels, and homeostasis model assessment-insulin resistance (HOMA-IR) were measured. Results: The mean serum IL-6 levels for groups 1, 2 and 3 were 14.65 ± 6.18 pg/mL, 16.22 ± 6.55 pg/mL, and 14:53 ± 7.32 pg/mL, respectively. There was no statically difference between three groups for serum IL-6 levels (p>0.05). For metabolic profile, the mean of HOMA-IR was 3.09±1.56 for group 2 and this was significantly lower than other groups (p

Kaynakça

  • The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consen- sus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1).19-25.
  • Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13):853-61.
  • Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87(8):3871-5.
  • Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Met- abolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60(1):39-51.
  • Bray GA. Medical consequences of obesity. J Clin En- docrinol Metab 2004;89(6):2583-9.
  • Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in poly- cystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21(6):1426-31.
  • Moscovitz H, Shofer F, Mignott H, Behrman A, Kil- patrick L. Plasma cytokine determinations in emer- gency department patients as a predictor of bacte- remia and infectious disease severity. Crit Care Med 1994;22(7):1102-7.
  • Villuendas G, San Millán JL, Sancho J, Escobar-Mor- reale HF. The -597 G-->A and -174 G-->C polymor- phisms in the promoter of the IL-6 gene are associ- ated with hyperandrogenism. J Clin Endocrinol Metab 2002;87(3):1134-41.
  • Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-al- pha- and obesity-induced insulin resistance. Science 1996;271(5249):665-8.
  • Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically de- fined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82(7):2248-56.
  • Legro RS, Chiu P, Kunselman AR, Bentley CM, Dod- son WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005;90(5):2571-9.
  • Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44(3):269-76.
  • Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
  • Endl J, Otto H, Jung G, et al. Identification of naturally processed T cell epitopes from glutamic acid decar- boxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 1997;99(10):2405-15.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess- ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
  • Genuth S, Alberti KG, Bennett P, et al. Expert Com- mittee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
  • Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggon- er W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white wom- en of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83(9):3078-82.
  • Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syn- drome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014- 21.
  • Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuti- cals at the crossroad of hormone replacement, anti- cancer and anti-inflammatory therapy. Biochem Phar- macol 2004;68(6):1171-85.
  • Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Elevated soluble tumor necrosis factor re- ceptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis 2004;177(1):77- 81.
  • Frishman WH. Biologic markers as predictors of car- diovascular disease. Am J Med 1998;104(6A):18S- 27S.
  • Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. En- docr Rev 2003;24(3):278-301.
  • Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med 2007;167(2):174-81.
  • Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86(6):2453-5.
  • Kovacs GT. Polycystic ovarian disease: an overview. Rev Gynaecol Pract 2004;2(4):97-104.
  • Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73(1):150-6.
  • Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thrifti- ness. Diabetologia 1999;42(11):1367-74.
  • Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148(2):209-14.

The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome

Yıl 2012, , 307 - 312, 01.09.2012
https://doi.org/10.5799/ahinjs.01.2012.03.0169

Öz

Amaç: Bu çalışmanın amacı polikistik over sendromunda (PKOS) biyokimyasal parametreler ve interleukin-6 ile over morfolojisi ilişkisini değerlendirmektir. Gereç ve yöntem: PKOS tanısı almış 85 hasta overlerin ultrasonografik değerlendirmesine göre; grup 1 ( polikistik görünümü olmayan, n = 22), grup 2 (bir overde polikistik görüntüsü olan, n = 41) ve grup 3 (her iki overde polikistik görüntüsü olan, n = 22) olmak üzere üç gruba ayrıldı. Hastaların serum interlökin 6 (IL-6), hormone düzeyleri ve homeostasis model assessment-insulin rezistans (HOMA-IR) değerleri ölçüldü. Bulgular: Serum IL-6 seviyeleri değerlendirildiğinde, ortalama değerler gruplar için sırasıyla 14.65±6.18 pg/mL, 16.22±6.55 pg/mL ve 14.53±7.32 pg/mL olarak bulundu. Serum IL-6 düzeyleri için üç grup arasında istatistiksel olarak anlamlı bir fark yoktu (p> 0.05). Metabolik profiling değerlendirmesinde ise HOMA-IR değeri grup 2 de 3,09±1,56 bulundu ve diğer gruplara göre anlamlı düzeyde düşüktü (p

Kaynakça

  • The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consen- sus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81(1).19-25.
  • Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13):853-61.
  • Yildiz BO, Haznedaroğlu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 2002;87(8):3871-5.
  • Orio F, Vuolo L, Palomba S, Lombardi G, Colao A. Met- abolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008;60(1):39-51.
  • Bray GA. Medical consequences of obesity. J Clin En- docrinol Metab 2004;89(6):2583-9.
  • Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in poly- cystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21(6):1426-31.
  • Moscovitz H, Shofer F, Mignott H, Behrman A, Kil- patrick L. Plasma cytokine determinations in emer- gency department patients as a predictor of bacte- remia and infectious disease severity. Crit Care Med 1994;22(7):1102-7.
  • Villuendas G, San Millán JL, Sancho J, Escobar-Mor- reale HF. The -597 G-->A and -174 G-->C polymor- phisms in the promoter of the IL-6 gene are associ- ated with hyperandrogenism. J Clin Endocrinol Metab 2002;87(3):1134-41.
  • Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-al- pha- and obesity-induced insulin resistance. Science 1996;271(5249):665-8.
  • Taylor AE, McCourt B, Martin KA, et al. Determinants of abnormal gonadotropin secretion in clinically de- fined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82(7):2248-56.
  • Legro RS, Chiu P, Kunselman AR, Bentley CM, Dod- son WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005;90(5):2571-9.
  • Birdsall MA, Farquhar CM. Polycystic ovaries in pre and post-menopausal women. Clin Endocrinol (Oxf) 1996;44(3):269-76.
  • Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
  • Endl J, Otto H, Jung G, et al. Identification of naturally processed T cell epitopes from glutamic acid decar- boxylase presented in the context of HLA-DR alleles by T lymphocytes of recent onset IDDM patients. J Clin Invest 1997;99(10):2405-15.
  • Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess- ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-9.
  • Genuth S, Alberti KG, Bennett P, et al. Expert Com- mittee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003;26(11):3160-7.
  • Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggon- er W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white wom- en of the southeastern United States: a prospective study. J Clin Endocrinol Metab 1998;83(9):3078-82.
  • Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Müller B. Central fat excess in polycystic ovary syn- drome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014- 21.
  • Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuti- cals at the crossroad of hormone replacement, anti- cancer and anti-inflammatory therapy. Biochem Phar- macol 2004;68(6):1171-85.
  • Rosenson RS, Tangney CC, Levine DM, Parker TS, Gordon BR. Elevated soluble tumor necrosis factor re- ceptor levels in non-obese adults with the atherogenic dyslipoproteinemia. Atherosclerosis 2004;177(1):77- 81.
  • Frishman WH. Biologic markers as predictors of car- diovascular disease. Am J Med 1998;104(6A):18S- 27S.
  • Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. En- docr Rev 2003;24(3):278-301.
  • Ranjit N, Diez-Roux AV, Shea S, et al. Psychosocial factors and inflammation in the multi-ethnic study of atherosclerosis. Arch Intern Med 2007;167(2):174-81.
  • Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86(6):2453-5.
  • Kovacs GT. Polycystic ovarian disease: an overview. Rev Gynaecol Pract 2004;2(4):97-104.
  • Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril 2000;73(1):150-6.
  • Fernández-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thrifti- ness. Diabetologia 1999;42(11):1367-74.
  • Yudkin JS, Kumari M, Humphries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 2000;148(2):209-14.
Toplam 28 adet kaynakça vardır.

Ayrıntılar

Birincil Dil Türkçe
Bölüm Araştırma Yazısı
Yazarlar

Sühha Mehmet Bostancı Bu kişi benim

Merih Bayram Bu kişi benim

Faika Ceylan Sevinç Bu kişi benim

Hatice Paşaoğlu Bu kişi benim

Şehri Elbeğ Bu kişi benim

Yayımlanma Tarihi 1 Eylül 2012
Yayımlandığı Sayı Yıl 2012

Kaynak Göster

APA Bostancı, S. M., Bayram, M., Sevinç, F. C., Paşaoğlu, H., vd. (2012). The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. Journal of Clinical and Experimental Investigations, 3(3), 307-312. https://doi.org/10.5799/ahinjs.01.2012.03.0169
AMA Bostancı SM, Bayram M, Sevinç FC, Paşaoğlu H, Elbeğ Ş. The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. J Clin Exp Invest. Eylül 2012;3(3):307-312. doi:10.5799/ahinjs.01.2012.03.0169
Chicago Bostancı, Sühha Mehmet, Merih Bayram, Faika Ceylan Sevinç, Hatice Paşaoğlu, ve Şehri Elbeğ. “The Relationship Between Biochemical Parameters, Interleukin-6 and Ovarian Morphology in Polycystic Ovary Syndrome”. Journal of Clinical and Experimental Investigations 3, sy. 3 (Eylül 2012): 307-12. https://doi.org/10.5799/ahinjs.01.2012.03.0169.
EndNote Bostancı SM, Bayram M, Sevinç FC, Paşaoğlu H, Elbeğ Ş (01 Eylül 2012) The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. Journal of Clinical and Experimental Investigations 3 3 307–312.
IEEE S. M. Bostancı, M. Bayram, F. C. Sevinç, H. Paşaoğlu, ve Ş. Elbeğ, “The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome”, J Clin Exp Invest, c. 3, sy. 3, ss. 307–312, 2012, doi: 10.5799/ahinjs.01.2012.03.0169.
ISNAD Bostancı, Sühha Mehmet vd. “The Relationship Between Biochemical Parameters, Interleukin-6 and Ovarian Morphology in Polycystic Ovary Syndrome”. Journal of Clinical and Experimental Investigations 3/3 (Eylül 2012), 307-312. https://doi.org/10.5799/ahinjs.01.2012.03.0169.
JAMA Bostancı SM, Bayram M, Sevinç FC, Paşaoğlu H, Elbeğ Ş. The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. J Clin Exp Invest. 2012;3:307–312.
MLA Bostancı, Sühha Mehmet vd. “The Relationship Between Biochemical Parameters, Interleukin-6 and Ovarian Morphology in Polycystic Ovary Syndrome”. Journal of Clinical and Experimental Investigations, c. 3, sy. 3, 2012, ss. 307-12, doi:10.5799/ahinjs.01.2012.03.0169.
Vancouver Bostancı SM, Bayram M, Sevinç FC, Paşaoğlu H, Elbeğ Ş. The relationship between biochemical parameters, interleukin-6 and ovarian morphology in polycystic ovary syndrome. J Clin Exp Invest. 2012;3(3):307-12.